High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit

Bert, F; Rindermann, A; Abdelfattah, Murad A.; Stahmeyer, Jona T.; Rossol, S.

doi:10.1097/meg.0000000000000702

Cited by 11 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten studies analyzed HCV prevalence among clinical populations ( 26 , 27 , 37 – 39 , 45 , 46 , 51 , 52 , 55 ), including one in HBV patients in care ( 55 ). Anti-HCV ranged from 0.2 to 5.2% with the lowest prevalence in autologous blood donors (giving blood for themselves).…”

Section: Resultsmentioning

confidence: 99%

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Sperle

Steffen

Leendertz

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

Background: One of the five strategic directions in the World Health Organization global health sector strategy on viral hepatitis 2016-2021 is to generate strong strategic information for focused action to understand the viral hepatitis epidemic and focus the response. Knowledge of national prevalence is a cornerstone of strategic information. Germany is considered to be a low prevalence country for viral hepatitis B, C, and D, however the prevalence is likely to be higher among at-risk groups. Methods: The aim of this work was to give a detailed overview of the prevalence of viral hepatitis B (HBsAg, anti-HBc), C (anti-HCV, HCV RNA), and D (anti-HDV, HDV RNA) in different population groups in Germany. Therefore, we analyzed the results of a comprehensive literature search on various aspects of the epidemiological situation of hepatitis B, C, and D in Germany. Eligible publications including information on hepatitis B, C, and D prevalence were extracted from the overall spreadsheet table and summarized and analyzed based on virus and different population groups. A quality appraisal was performed using a checklist developed by Hoy et al. to assess risk of bias in prevalence studies. Results: Overall, 51 publications were identified through the literature search. The overall prevalence of HBsAg in the general (and proxy) population ranged from 0.3 to 1.6%. Among at-risk groups, including clinical populations and health care workers, the HBsAg prevalence ranged from 0.2% (among rheumatic patients) to 4.5% among HIV positive patients. The overall prevalence of anti-HCV in the general (and proxy) population ranged from 0.2 to 1.9%. Among at-risk groups, including clinical populations and health care workers, the anti-HCV prevalence ranged from 0.04% (among health care workers) to 68.0% among people who inject drugs. Conclusions: The hepatitis B and C prevalence in the general population in Germany is low. Prevalence is high to very high among at-risk populations, however for some Sperle et al. Hepatitis B, C, and D Prevalence groups evidence was incomplete or missing completely. To reach the elimination goals in Germany and implement a targeted response, more research among at-risk groups is needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Sperle

Steffen

Leendertz

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…In Picardy, France, testing was only performed after a risk assessment questionnaire, and only patients with at least one risk factor were screened for HCV Ab . In Germany, two large‐scale studies were performed in urban areas in Berlin and Frankfurt/Mainz . Main risk factors were migration and PWID.…”

Section: Discussionmentioning

confidence: 99%

“…18 In Germany, two large-scale studies were performed in urban areas in Berlin and Frankfurt/ Mainz. 19,22 Main risk factors were migration and PWID. The location of these clinics in large cities explained the higher prevalence of these risk factors as compared to the general population in Germany.…”

Section: Discussionmentioning

confidence: 99%

“…Higher rates of HCV Ab (2.5%‐3.5%) have been reported in European emergency departments (ED) compared to the general population . In the USA, because of the presence of a large number of high‐risk patients, prevalence was even higher ranging from 9.5%‐18.0% .…”

Section: Introductionmentioning

confidence: 99%

“…16,17 Higher rates of HCV Ab (2.5%-3.5%) have been reported in European emergency departments (ED) compared to the general population. [18][19][20][21][22] In the USA, because of the presence of a large number of high-risk patients, prevalence was even higher ranging from 9.5%-18.0%. [23][24][25][26] According to these studies, screening at the ED would also be cost-effective.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium?

Bielen

Kremer

Koc

et al. 2018

Liver International

View full text Add to dashboard Cite

Background & Aims Patients are not screened adequately for hepatitis C virus infection in Belgium. In the USA, the Center for Disease Control recommends screening for patients born in the babyboom period (1945‐1965). In Europe, the babyboom cohort was born between 1955 and 1974, but no screening policy has been targeted to this group. We aimed to study the prevalence of hepatitis C virus in an emergency department population in Belgium and the risk factors associated with hepatitis C virus infection. Method We performed a monocentric, cross‐sectional seroprevalence study between January and November 2017 in a large Belgian non‐university hospital. Patients aged 18‐70 years presenting at the emergency department were eligible. Patients completed a risk assessment questionnaire and were screened for hepatitis C virus antibodies (Ab) with reflex hepatitis C virus ribonucleic acid testing. Results Of 2970 patients, 2366 (79.7%) agreed to participate. hepatitis C virus Ab prevalence was 1.31%. Twenty‐one (67.7%) hepatitis C virus Ab‐positive patients were born between 1955 and 1974. With a previous treatment uptake of 54.5%, the prevalence of viremia was 0.9% in retrospect; 0.2% were newly diagnosed. The weighted multiple logistic regression model identified males born in the 1955‐1974 cohort, intravenous drug use and high endemic birth country as significant risk factors for hepatitis C virus infection (P < 0.05). Conclusion Although the prevalence of hepatitis C virus Ab at the emergency department was higher than previously estimated for the general population in Belgium, the number of newly diagnosed patients with viremia was low. To optimize screening strategies, screening should be offered to males born in the 1955‐1974 cohort, but especially in drug users, the prison population and immigrants from high endemic countries.

show abstract

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection

Wang

Jiang

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective: To discuss the clinical significance of HCV-cAg testing in the diagnosis, activity determination, and monitoring of therapeutic effectiveness of HCV infection and its advantages compared with HCV-RNA and anti-HCV antibodies detection. Methods:By summarizing the published literature, the advantages and significance of HCV core antigen detection were sought.Results: The expression of HCV-cAg is highly consistent with that of HCV-RNA, but compared with HCV-RNA, detection of HCV-cAg is easy to operate, time saving, and low cost. HCV-cAg can be detected within 12~15 days after infection, and the window period can be shortened by5~7 weeks. HCV-cAg is a serological indicator of virus replication, which can distinguish previous infection of HCV or current infection.HCV-cAg detection is more suitable for immunocompromised, hemodialysis, organ transplant patients. HCV-cAg also can be used to monitor antiviral efficacy and predict sustained virological response (SVR). Conclusion:HCV core antigen has similar clinical sensitivity to NAT and can be used as a substitute for HCV-RNA in the diagnosis of virus infection. Combined detection of HCV-cAg and antibody serology can help doctors detect HCV infection earlier, accurately diagnose different stages of HCV infection, and evaluate the therapeutic effect of antiviral drugs, which are beneficial in the prevention and treatment of hepatitis C.

show abstract

High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit

Abstract: The results show that in multicultural areas, the prevalence of chronic viral hepatitis is increased. Because of the potential of progressive liver damage in viral hepatitis, field screening in specific populations at high risk for hepatitis should be performed.

Cited by 11 publications

References 39 publications

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review

Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium?

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection

Contact Info

Product

Resources

About